menu
    • menu
    [{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Seralutinib","moa":"PDGFR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.12,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ EcoR1 Capital"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Seralutinib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Seralutinib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.20999999999999999,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ New Enterprise Associates","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ New Enterprise Associates"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Seralutinib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.33000000000000002,"dosageForm":"Powder In Capsule","sponsorNew":"Gossamer Bio \/ Chiesi Group","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ Chiesi Group"}]

    Find Clinical Drug Pipeline Developments & Deals for Seralutinib

    Menu

    Seralutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Chiesi Group

                            Deal Size : $326.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gossamer Bio and Chiesi Group Collaborate to Develop Seralutinib for PAH and PH-ILD

                            Details : Gossamer Bio continues developing GB002 (seralutinib), an inhaled inhibitor for pulmonary hypertension, while Chiesi will commercialize it outside the U.S.

                            Brand Name : GB002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 06, 2024

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Chiesi Group

                            Deal Size : $326.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : New Enterprise Associates

                            Deal Size : $212.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Gossamer Bio Announces $212 Million Private Placement Financing

                            Details : Gossamer intends to use the net proceeds to fund the ongoing development and commercialization of GB002 (seralutinib), a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, for the treatment of pulmonary arterial hypertension (PAH).

                            Brand Name : GB002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : New Enterprise Associates

                            Deal Size : $212.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

                            Details : The efficacy results generated with GB002 (seralutinib) in the context of a favorable safety and tolerability profile highlight compelling potential differentiation for seralutinib as an anti-proliferative, anti-inflammatory, and anti-fibrotic therapeuti...

                            Brand Name : GB002

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 06, 2022

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Gossamer Bio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : EcoR1 Capital

                            Deal Size : $120.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Gossamer Bio Announces $120 Million Private Placement Financing

                            Details : Gossamer intends to use the net proceeds from the proposed financing to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes.

                            Brand Name : GB002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 13, 2022

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : EcoR1 Capital

                            Deal Size : $120.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gossamer Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Gossamer Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Se...

                            Details : Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with WHO Group 1 PAH who are Functional Class II and III.

                            Brand Name : GB002

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : Seralutinib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth